ArticleScientific reports2026
Disruption of NLRP3 inflammasome assembly via ligand-induced remodeling of pyrin domain interfaces.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The inflammasome is a multimeric intracellular complex that regulates caspase-1 activity in innate immunity, with NLRP3 serving as a central mediator of inflammatory responses. Despite extensive efforts, effective inhibitors of NLRP3 oligomerization remain limited. Here, we screened a library of small molecules and identified four candidates that disrupt homo-oligomerization of the NLRP3 pyrin domain (PYD). Among these, compound E9 exhibited superior affinity and specificity, as confirmed by split-luciferase complementation assays, microscale thermophoresis (Kd < 1 µM), molecular docking, and molecular dynamics simulations. Mechanistic analyses revealed that E9 binding induces targeted structural and dynamic remodeling of the PYD filament, dampening dominant collective motions and disrupting cooperative inter-subunit interactions. These changes reduce the filament's conformational flexibility and impair its ability to recruit ASC, thereby inhibiting inflammasome activation in THP1-ASC-GFP cells, as evidenced by suppression of speck formation. Overall, our study identifies E9 as a potent inhibitor of NLRP3 oligomerization and highlights interface-specific modulation of filament dynamics as a promising strategy for developing next-generation inflammasome-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.